Real‐life effectiveness of Risankizumab according to body mass index: Results of an Italian multicentre retrospective studyMartina Dragotto, Emanuele Trovato, Susanna Rossari et al.|Journal of the European Academy of Dermatology and Venereology|2023Cited by 8
Efficacy of risankizumab after intra-class switching between anti IL-23 antagonists: a multi-center, retrospective, real-life observationFlavia Manzo Margiotta, Francesca Prignano, Alessandra Michelucci et al.|Italian Journal of Dermatology and Venereology|2023Cited by 4
Risankizumab in Oncologic Patients With Psoriasis: A Case SeriesMichela Magnano, Francesca Prignano, Susanna Rossari et al.|JEADV Clinical Practice|2024Cited by 3
Risankizumab in very elderly patients in real-world practiceE Lorenzoni, Francesca Prignano, Antonella Di Cesare et al.|Italian Journal of Dermatology and Venereology|2024Cited by 2
Therapeutic Modulation Of Peripheral Blood Cells And Inflammatory Indices During 52 Weeks Of Risankizumab In Responder Patients With Moderate-to-Severe Psoriasis: Results From A Multicenter Prospective StudyAntonella Di Cesare, Francesca Prignano, Elia Rosi et al.|Dermatology Practical & Conceptual|2025Cited by 1